CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company developing chimeric engulfment receptor T-cell, or CER-T, therapies targeting solid tumor and hematologic cancers. The company emerged from a de-SPAC transaction with Phoenix Biotech Acquisition Corp, a blank-check vehicle that completed its IPO in 2021 and was sponsored by Phoenix Biotech Sponsor LLC. CERO filed its 10-Q quarterly report with the SEC on August 11, 2022, reflecting its ongoing development-stage operations within the oncology and cell therapy sector. The company is focused on advancing its proprietary CER-T platform through clinical evaluation. Sign up for full data on SpacDesk to access CERO's complete filing history, transaction timeline, and sponsor profile.